Invasion of Tumorigenic HT1080 Cells Is Impeded by Blocking or Downregulating the 37-kDa/67-kDa Laminin Receptor

Zuber, Chantal; Knackmuss, Stefan; Zemora, Georgeta; Reusch, Uwe; Vlasova, E. V.; Diehl, Daniela; Mick, Vera; Hoffmann, K.; Nikles, Daphne; Fröhlich, Thomas; Arnold, Georg J.; Brenig, Bertram; Wolf, Eckhard; Lahm, Harald; Little, Melvyn; Weiß, Stefan

doi:10.1016/j.jmb.2008.02.004

Cited by 57 publications

(81 citation statements)

References 41 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, both antibodies suppressed A20 cell attachment to components of the extracellular matrix especially laminin. Inhibition of laminin attachment is consistent with what has been reported previously with antibodies that targets both the immature and mature forms of the laminin receptor protein [29][30][31] or with treatments that down-regulate expression of the 37 k D /67 kD laminin receptor. 30 If such inhibition occurred in the circulation, it might delay tumor cell egress from the blood stream and as a consequence, lead to more efficient intravascular cell killing (by whatever mechanisms).…”

Section: Discussionsupporting

confidence: 90%

Monoclonal antibodies specific for oncofetal antigen – immature laminin receptor protein: Effects on tumor growth and spread in two murine models

McClintock

Warner

Ali

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

The oncofetal antigen -immature laminin receptor protein (OFA/iLRP) has been linked to metastatic tumor spread for several years. The present study, in which 2 highly-specific, high-affinity OFA/iLRP-reactive mouse monoclonal antibodies were examined for ability to suppress tumor cell growth and metastatic spread in the A20 B-cell leukemia model and the B16 melanoma model, provides the first direct evidence that targeting OFA/iLRP with exogenous antibodies can have therapeutic benefit. While the antibodies were modestly effective at preventing tumor growth at the primary injection site, both antibodies strongly suppressed end-organ tumor formation following intravenous tumor cell injection. Capacity of anti-OFA/iLRP antibodies to suppress tumor spread through the blood in the leukemia model suggests their use as a therapy for individuals with leukemic disease (either for patients in remission or even as part of an induction therapy). The results also suggest use against metastatic spread with solid tumors.

show abstract

Section: Discussionsupporting

confidence: 90%

Monoclonal antibodies specific for oncofetal antigen – immature laminin receptor protein: Effects on tumor growth and spread in two murine models

McClintock

Warner

Ali

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…44 Interestingly, reagents directed against LRP/LR or LRP mRNA were able to inhibit the invasion potential of fibrosarcoma cells. 45 Since PrP C is able to modulate the activity of membrane proteins such as a v b 3 integrin, 11 it is possible that PrP C could negatively influence the metastatic activity of LRP/LR either by direct binding or by competing by laminin interaction. Thus, in the absence of PrP C , LRP/LR could present increased metastatic potential.…”

Section: Discussionmentioning

confidence: 99%

Prion protein ablation increases cellular aggregation and embolization contributing to mechanisms of metastasis

Muras¹,

Hajj²,

Ribeiro

et al. 2009

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Monoclonal antibody IgG1-HD37 (Sigma-Aldrich) possessing the same format as primary antibody IgG1-iS18 is directed against CD19 on β-lymphocytes in humans. The full-length antibody IgG1-iS18 was recombinantly produced in a mammalian expression system as previously described by Zuber et al (6).…”

Section: Reagents and Antibodiesmentioning

confidence: 99%

“…LRP/LR is a nonintegrin cell surface receptor located in the extracellular matrix of mammalian cells (6,7). While LRP/LR predominantly functions as a transmembrane receptor (8), it has also been found in the nucleus, where it interacts with histones and chromatin (9), as well as in the cytosol, where it aids in translation and ribosomal deaths (http://www.wcrf.org/int/ cancer-facts-figures/worldwide-data).…”

mentioning

confidence: 99%

Anti-LRP/LR-Specific Antibody IgG1-iS18 Significantly Impedes Adhesion and Invasion in Early- and Late-Stage Colorectal Carcinoma Cells

Vania

Chetty

Ferreira

et al. 2016

Mol Med

View full text Add to dashboard Cite

Cancer is a highly complex disease that has become one of the leading causes of death globally. Metastasis, a major cause of cancer deaths, requires two crucial events, adhesion and invasion. The 37kDa/67kDa laminin receptor (laminin receptor precursor/high-affinity laminin receptor [LRP/LR]) enhances these two steps, consequently aiding in cancer progression. In this study, the role of LRP/LR in adhesion and invasion of early-stage (SW-480 and HT-29) and late-stage (DLD-1) colorectal cancer cells was investigated. Western blotting revealed that early-and late-stage colorectal cancer cells contained significantly higher total LRP/LR levels compared with poorly invasive MCF-7 breast cancer control cells. Flow cytometry revealed that both stages of colorectal cancer displayed significantly higher cell surface LRP/LR levels. Furthermore, upon treatment of colorectal cancer cells with the anti-LRP/LR-specific antibody IgG1-iS18, adhesion to laminin-1 was significantly reduced in both stages. Each stage's invasive potential was determined using the Matrigel™ invasion assay, showing that invasion was significantly impeded in both colorectal cancer stages when the cells were incubated with IgG1-iS18. In addition, Pearson's correlation coefficients propose that both total and cell surface LRP/LR levels are directly proportional to the adhesive and invasive potential of both stages of colorectal cancer. Hence, these findings indicate potential for use of the IgG1-iS18 antibody as a promising therapeutic tool for colorectal cancer patients at both stages.

show abstract

Invasion of Tumorigenic HT1080 Cells Is Impeded by Blocking or Downregulating the 37-kDa/67-kDa Laminin Receptor

Cited by 57 publications

References 41 publications

Monoclonal antibodies specific for oncofetal antigen – immature laminin receptor protein: Effects on tumor growth and spread in two murine models

Monoclonal antibodies specific for oncofetal antigen – immature laminin receptor protein: Effects on tumor growth and spread in two murine models

Prion protein ablation increases cellular aggregation and embolization contributing to mechanisms of metastasis

Anti-LRP/LR-Specific Antibody IgG1-iS18 Significantly Impedes Adhesion and Invasion in Early- and Late-Stage Colorectal Carcinoma Cells

Contact Info

Product

Resources

About